• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用STORM超分辨率显微镜对原代人T细胞上的嵌合抗原受体进行直接可视化。

Direct visualization of chimeric antigen receptors on primary human T cells using STORM super-resolution microscopy.

作者信息

Gehrke Leon, Seifert Nicole, Spieler Peter, Verbruggen Christina, Seifert Rick, Toppeta Fabio, Krick Maximilian, Doose Sören, Einsele Hermann, Hudecek Michael, Sauer Markus, Nerreter Thomas

机构信息

Chair of Cellular Immunotherapy, Department of Internal Medicine II, University Hospital Würzburg (UKW), Würzburg, Germany.

Department of Biotechnology and Biophysics, Biocenter, Am Hubland, University of Würzburg, Würzburg, Germany.

出版信息

Front Immunol. 2025 Aug 1;16:1632823. doi: 10.3389/fimmu.2025.1632823. eCollection 2025.

DOI:10.3389/fimmu.2025.1632823
PMID:40821773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12354347/
Abstract

Chimeric antigen receptor (CAR) T cells are a transformative treatment for hematological malignancies, and concerted efforts in the field are aiming to translate this success to solid tumors and autoimmune diseases. There is a desire in the field to accurately assess CAR organization and spatiotemporal expression to elucidate mechanistic details of CAR-T cell mediated anti-tumor activity and enable evaluation of the potency and safety of CAR-T cell products. We applied an IgG4-targeted F(ab) to achieve direct CAR labeling for super-resolution microscopy by stochastic optical reconstruction microscopy (STORM). This enabled us to determine CAR surface expression on human primary T cells with single-molecule resolution independent of CAR specificity. We combined this direct CAR detection approach with a phenotypic assessment of the CAR-T cells, highlighting prospective applications to gain detailed mechanistic insights. With this new approach, we were able to detect the surface expression of CARs targeting SLAMF7, BCMA and CD19 with minimal background. We determined T cell subtype, donor material, and CAR construct as contributing factors shaping CAR surface expression and identified putative influence of CAR surface expression on CAR-T cell activation state. Here we provide a novel, tag-free approach to gain insights into the surface expression of CARs, illustrating the potential of super-resolution microscopy to inform the application of synthetic immune receptors for CAR-T cell therapy, potentially building the basis for more intricate and combinatorial studies to further improve the efficacy of CAR-T cell immunotherapy, predict therapeutic outcome and ensure optimal care for patients.

摘要

嵌合抗原受体(CAR)T细胞是血液系统恶性肿瘤的一种变革性治疗方法,该领域正在共同努力将这一成功应用于实体瘤和自身免疫性疾病。该领域希望准确评估CAR的组织形式和时空表达,以阐明CAR-T细胞介导的抗肿瘤活性的机制细节,并能够评估CAR-T细胞产品的效力和安全性。我们应用了一种靶向IgG4的F(ab)片段,通过随机光学重建显微镜(STORM)实现对CAR的直接标记,用于超分辨率显微镜观察。这使我们能够以单分子分辨率确定人原代T细胞上的CAR表面表达,而与CAR的特异性无关。我们将这种直接CAR检测方法与CAR-T细胞的表型评估相结合,突出了其在获取详细机制见解方面的潜在应用。通过这种新方法,我们能够以最小的背景检测靶向信号淋巴细胞激活分子家族成员7(SLAMF7)、B细胞成熟抗原(BCMA)和CD19的CAR的表面表达。我们确定T细胞亚型、供体材料和CAR构建体是影响CAR表面表达的因素,并确定了CAR表面表达对CAR-T细胞激活状态的潜在影响。在这里,我们提供了一种新颖的、无标签的方法来深入了解CAR的表面表达,展示了超分辨率显微镜在为CAR-T细胞疗法的合成免疫受体应用提供信息方面的潜力,这可能为更复杂和组合性的研究奠定基础,以进一步提高CAR-T细胞免疫疗法的疗效、预测治疗结果并确保为患者提供最佳护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/1b54b6e67b86/fimmu-16-1632823-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/2daf99406213/fimmu-16-1632823-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/ddacf4b573aa/fimmu-16-1632823-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/b39bd0ceeb9b/fimmu-16-1632823-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/1b54b6e67b86/fimmu-16-1632823-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/2daf99406213/fimmu-16-1632823-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/ddacf4b573aa/fimmu-16-1632823-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/b39bd0ceeb9b/fimmu-16-1632823-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e30f/12354347/1b54b6e67b86/fimmu-16-1632823-g004.jpg

相似文献

1
Direct visualization of chimeric antigen receptors on primary human T cells using STORM super-resolution microscopy.使用STORM超分辨率显微镜对原代人T细胞上的嵌合抗原受体进行直接可视化。
Front Immunol. 2025 Aug 1;16:1632823. doi: 10.3389/fimmu.2025.1632823. eCollection 2025.
2
A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14CD127 T cells for chimeric antigen receptor T-cell manufacture.用于嵌合抗原受体T细胞疗法的新型细胞——分离用于制造嵌合抗原受体T细胞的CD14CD127 T细胞。
Cytotherapy. 2025 Apr 18. doi: 10.1016/j.jcyt.2025.04.068.
3
Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma.利用CARtein系统对BCMA和SLAMF7进行双重靶向:具有内含肽介导剪接的嵌合抗原受体引发针对多发性骨髓瘤的特异性T细胞活化。
Front Immunol. 2025 Jul 31;16:1613222. doi: 10.3389/fimmu.2025.1613222. eCollection 2025.
4
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology.血液肿瘤学中除CD19和BCMA之外的新型嵌合抗原受体T细胞(CAR-T)疗法的未来展望
Front Immunol. 2025 Jul 14;16:1592377. doi: 10.3389/fimmu.2025.1592377. eCollection 2025.
5
Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells.用于减少嵌合抗原受体T细胞制造过程中T细胞耗竭的生物功能水凝胶涂层膜。
Front Immunol. 2025 Jun 27;16:1513148. doi: 10.3389/fimmu.2025.1513148. eCollection 2025.
6
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.嵌合抗原受体 T 细胞疗法治疗胶质母细胞瘤:分子靶点和治疗策略的系统评价。
Int J Mol Sci. 2024 Jun 29;25(13):7174. doi: 10.3390/ijms25137174.
7
Obecabtagene autoleucel, a novel CD19-directed CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: the future for reducing toxicity and T-cell exhaustion?奥贝卡他基因自体白细胞介素,一种用于复发/难治性B细胞急性淋巴细胞白血病的新型CD19导向嵌合抗原受体T细胞疗法:降低毒性和T细胞耗竭的未来希望?
Expert Rev Hematol. 2025 Jun 23. doi: 10.1080/17474086.2025.2523551.
8
In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.基于体外机器学习的 CAR T 免疫突触质量测量与患者临床结果相关。
PLoS Comput Biol. 2022 Mar 18;18(3):e1009883. doi: 10.1371/journal.pcbi.1009883. eCollection 2022 Mar.
9
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia.外周血计数低和促炎细胞因子升高提示急性淋巴细胞白血病患者CD19嵌合抗原受体T细胞反应不佳。
Transplant Cell Ther. 2025 May 20. doi: 10.1016/j.jtct.2025.05.003.
10
Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.用编码嵌合抗原受体的狒狒包膜假型慢病毒载体转导γδ T细胞,用于转化研究和临床应用。
Front Immunol. 2025 Jun 6;16:1548630. doi: 10.3389/fimmu.2025.1548630. eCollection 2025.

本文引用的文献

1
Decoding the molecular interplay of CD20 and therapeutic antibodies with fast volumetric nanoscopy.利用快速体积纳米显微镜解码CD20与治疗性抗体的分子相互作用。
Science. 2025 Jan 10;387(6730):eadq4510. doi: 10.1126/science.adq4510.
2
Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CAR NK cells.针对基于单链抗体片段(scFv)的嵌合抗原受体自然杀伤细胞(CAR NK细胞),接头特异性单克隆抗体提供了一种简单可靠的检测方法。
Mol Ther Methods Clin Dev. 2024 Aug 22;32(3):101328. doi: 10.1016/j.omtm.2024.101328. eCollection 2024 Sep 12.
3
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
用于复发/难治性慢性淋巴细胞白血病的第三代抗 CD19 CAR T 细胞:一项 1/2 期研究。
Leukemia. 2024 Nov;38(11):2419-2428. doi: 10.1038/s41375-024-02392-7. Epub 2024 Aug 27.
4
Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells.共刺激受体对TCR-T细胞中细胞因子产生时间的调节在CAR-T细胞中丧失。
Immunother Adv. 2024 Jun 19;4(1):ltae004. doi: 10.1093/immadv/ltae004. eCollection 2024.
5
and analysis reveal impact of c-Myc tag in FMC63 scFv-CD19 protein interface and CAR-T cell efficacy.分析揭示了c-Myc标签在FMC63单链抗体片段-CD19蛋白界面及嵌合抗原受体T细胞疗效中的影响。
Comput Struct Biotechnol J. 2024 May 19;23:2375-2387. doi: 10.1016/j.csbj.2024.05.032. eCollection 2024 Dec.
6
Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape.CAR 分子的胞吞作用调节 CAR-T 细胞功能障碍和肿瘤抗原逃逸。
Signal Transduct Target Ther. 2023 Dec 25;8(1):457. doi: 10.1038/s41392-023-01708-w.
7
Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.FADD/BID 信号受损介导多发性骨髓瘤对免疫治疗的交叉耐药。
Commun Biol. 2023 Dec 21;6(1):1299. doi: 10.1038/s42003-023-05683-4.
8
Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞疗法治疗弥漫性大 B 细胞淋巴瘤的真实世界结局:系统评价和荟萃分析。
Transplant Cell Ther. 2024 Jan;30(1):77.e1-77.e15. doi: 10.1016/j.jtct.2023.10.017. Epub 2023 Oct 27.
9
CAR T therapy beyond cancer: the evolution of a living drug.CAR T 疗法超越癌症:活药物的演变。
Nature. 2023 Jul;619(7971):707-715. doi: 10.1038/s41586-023-06243-w. Epub 2023 Jul 26.
10
Activation-inducible CAR expression enables precise control over engineered CAR T cell function.激活诱导型 CAR 表达可实现对工程 CAR T 细胞功能的精确控制。
Commun Biol. 2023 Jun 5;6(1):604. doi: 10.1038/s42003-023-04978-w.